| Literature DB >> 25637603 |
Stuart Maudsley1, Bronwen Martin2, Diane Gesty-Palmer2, Huey Cheung2, Calvin Johnson2, Shamit Patel2, Kevin G Becker2, William H Wood2, Yongqing Zhang2, Elin Lehrmann2, Louis M Luttrell2.
Abstract
Biased G protein-coupled receptor agonists engender a restricted repertoire of downstream events from their cognate receptors, permitting them to produce mixed agonist-antagonist effects in vivo. While this opens the possibility of novel therapeutics, it complicates rational drug design, since the in vivo response to a biased agonist cannot be reliably predicted from its in cellula efficacy. We have employed novel informatic approaches to characterize the in vivo transcriptomic signature of the arrestin pathway-selective parathyroid hormone analog [d-Trp(12), Tyr(34)]bovine PTH(7-34) in six different murine tissues after chronic drug exposure. We find that [d-Trp(12), Tyr(34)]bovine PTH(7-34) elicits a distinctive arrestin-signaling focused transcriptomic response that is more coherently regulated across tissues than that of the pluripotent agonist, human PTH(1-34). This arrestin-focused network is closely associated with transcriptional control of cell growth and development. Our demonstration of a conserved arrestin-dependent transcriptomic signature suggests a framework within which the in vivo outcomes of arrestin-biased signaling may be generalized. U.S. Government work not protected by U.S. copyright.Entities:
Mesh:
Substances:
Year: 2015 PMID: 25637603 PMCID: PMC4366796 DOI: 10.1124/mol.114.095224
Source DB: PubMed Journal: Mol Pharmacol ISSN: 0026-895X Impact factor: 4.436